CS
MRSN

Credit Suisse’s Mersana Therapeutics MRSN Stock Holding History

Credit Suisse’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,163
Closed -$164K – 3113
2023
Q3 		$164K Sell
5,163
-776
-13% -$36.9K ﹤0.01% 3057
2023
Q2 		$488K Buy
5,939
+1,784
+43% +$261K ﹤0.01% 2792
2023
Q1 		$427K Buy
4,155
+256
+7% +$35.9K ﹤0.01% 2829
2022
Q4 		$571K Sell
3,899
-208
-5% -$35.2K ﹤0.01% 2699
2022
Q3 		$693K Buy
4,107
+885
+27% +$144K ﹤0.01% 2585
2022
Q2 		$373K Buy
3,222
+184
+6% +$17.3K ﹤0.01% 3035
2022
Q1 		$304K Buy
3,038
+369
+14% +$43.1K ﹤0.01% 3217
2021
Q4 		$415K Buy
2,669
+585
+28% +$114K ﹤0.01% 3950
2021
Q3 		$492K Sell
2,084
-82
-4% -$24K ﹤0.01% 3807
2021
Q2 		$736K Buy
2,166
+28
+1% +$10.6K ﹤0.01% 3596
2021
Q1 		$863K Sell
2,138
-2,392
-53% -$1.16M ﹤0.01% 3418
2020
Q4 		$3.01M Buy
4,530
+20
+0.4% +$11.1K ﹤0.01% 2520
2020
Q3 		$2.1M Buy
4,510
+2,199
+95% +$1.11M ﹤0.01% 2386
2020
Q2 		$1.35M Buy
+2,311
New +$789K ﹤0.01% 2692
2019
Q4 		– Sell
-435
Closed -$17K – 4272
2019
Q3 		$17K Buy
+435
New +$31.6K ﹤0.01% 4090

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Credit Suisse's MRSN Position: Q4 2023 in Review

Credit Suisse sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 5,163 shares — an estimated $164K sold.

Credit Suisse first reported a position in MRSN in Q3 2019 and held it in 15 quarters. The position peaked at $3.01M in Q4 2020. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Credit Suisse reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 5,163 Mersana Therapeutics shares in Q4 2023, an estimated $164K.
  • Credit Suisse first reported a position in Mersana Therapeutics in Q3 2019 and held it in 15 quarters.
  • Credit Suisse's Mersana Therapeutics position peaked at $3.01M in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.